Eosinophilic cationic protein: is it useful in assessing control of childhood asthma?

M Zedan1, A Settin, F El-Chennawi

  • 1Allergy, Respiratory and Clinical Immunology Unit, Faculty of Medicine, University of Mansoura, Mansoura, Egypt. magdyzedan@mans.edu.eg

Insights

Peripheral eosinophil counts and serum eosinophilic cationic protein (s-ECP) can help assess asthma control in children. Higher levels indicate poorer asthma control, suggesting these markers aid in evaluating disease management.

Area of Science:

  • Pediatric Pulmonology
  • Allergy and Immunology
  • Biomarker Research

Background:

  • Asthma control assessment is crucial for managing pediatric cases.
  • Peripheral eosinophils and serum eosinophilic cationic protein (s-ECP) are potential biomarkers.
  • Objective evaluation of these markers in pediatric asthma is needed.

Purpose of the Study:

  • To evaluate peripheral eosinophil and s-ECP levels as indicators of asthma control in children.
  • To compare these marker levels between children with controlled, partially controlled asthma, and healthy controls.
  • To determine the correlation between marker levels and the degree of asthma control.

Main Methods:

  • Cross-sectional study comparing 38 children with asthma (16 controlled, 22 partially controlled) and 16 healthy children.
  • Measurement of peripheral eosinophil counts and serum eosinophilic cationic protein (s-ECP) levels.
  • Statistical analysis to compare groups and assess correlations.

Main Results:

  • Children with asthma exhibited higher eosinophil counts and s-ECP levels than healthy children.
  • Partially controlled asthmatics showed significantly higher levels of both markers compared to controlled asthmatics.
  • A strong negative correlation was observed between asthma control and both peripheral eosinophil counts (r = -0.60) and s-ECP levels (r = -0.75).

Conclusions:

  • Peripheral eosinophil count and s-ECP are valuable tools for assessing asthma control in pediatric patients.
  • These biomarkers can help differentiate between controlled and partially controlled asthma.
  • Monitoring these markers may aid in optimizing asthma management strategies.

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...